| Muhammad Shoaib Akbar, MD | |
|
1325 Andrea St, Ste 207, Bowling Green, KY 42104-5852 | |
| (270) 846-3811 | |
| (270) 846-3812 |
| Full Name | Muhammad Shoaib Akbar |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 21 Years |
| Location | 1325 Andrea St, Bowling Green, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1326231622 | NPI | - | NPPES |
| 7100243210 | Medicaid | KY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 42769 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| The Medical Center (bowling Green) | Bowling green, KY | Hospital |
| Greenview Regional Hospital | Bowling green, KY | Hospital |
| The Medical Center At Scottsville | Scottsville, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Western Kentucky Heartand Lung Associates Psc | 9537103189 | 15 |
News Archive
A new study by researchers at the UCLA Jonsson Comprehensive Cancer Center sheds light on how interferon-gamma (IFN-y), an immune response-stimulating signaling molecule that helps activate immune cells, guides the treatment response in people with advanced melanoma who are treated with one of the leading immunotherapies -; immune checkpoint blockade.
Gene therapy that boosts the ability of brain cells to gobble up toxic proteins prevents development of Alzheimer's disease in mice that are predestined to develop it, report researchers at Georgetown University Medical Center. They say the treatment - which is given just once - could potentially do the same in people at the beginning stages of the disease.
Cadence Pharmaceuticals, Inc., a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that it has signed an agreement providing Cadence with an exclusive option to acquire Incline Therapeutics, Inc., a privately held specialty pharmaceutical company.
The performance of commercially available serological tests in real patient samples and the correlates of immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) provided by IgG antibodies are still a matter of debate. A new bioRxiv preprint paper cross-examines the performance of several assays and proclaims the plaque reduction neutralization test (PRNT) as a method of choice.
› Verified 8 days ago
| Entity Name | Western Kentucky Heart& Lung Associates Psc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881692861 PECOS PAC ID: 9537103189 Enrollment ID: O20050614001056 |
News Archive
A new study by researchers at the UCLA Jonsson Comprehensive Cancer Center sheds light on how interferon-gamma (IFN-y), an immune response-stimulating signaling molecule that helps activate immune cells, guides the treatment response in people with advanced melanoma who are treated with one of the leading immunotherapies -; immune checkpoint blockade.
Gene therapy that boosts the ability of brain cells to gobble up toxic proteins prevents development of Alzheimer's disease in mice that are predestined to develop it, report researchers at Georgetown University Medical Center. They say the treatment - which is given just once - could potentially do the same in people at the beginning stages of the disease.
Cadence Pharmaceuticals, Inc., a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that it has signed an agreement providing Cadence with an exclusive option to acquire Incline Therapeutics, Inc., a privately held specialty pharmaceutical company.
The performance of commercially available serological tests in real patient samples and the correlates of immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) provided by IgG antibodies are still a matter of debate. A new bioRxiv preprint paper cross-examines the performance of several assays and proclaims the plaque reduction neutralization test (PRNT) as a method of choice.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Muhammad Shoaib Akbar, MD 825 2nd Ave, Ste. B1, Bowling Green, KY 42101-1786 Ph: (270) 782-0151 | Muhammad Shoaib Akbar, MD 1325 Andrea St, Ste 207, Bowling Green, KY 42104-5852 Ph: (270) 846-3811 |
News Archive
A new study by researchers at the UCLA Jonsson Comprehensive Cancer Center sheds light on how interferon-gamma (IFN-y), an immune response-stimulating signaling molecule that helps activate immune cells, guides the treatment response in people with advanced melanoma who are treated with one of the leading immunotherapies -; immune checkpoint blockade.
Gene therapy that boosts the ability of brain cells to gobble up toxic proteins prevents development of Alzheimer's disease in mice that are predestined to develop it, report researchers at Georgetown University Medical Center. They say the treatment - which is given just once - could potentially do the same in people at the beginning stages of the disease.
Cadence Pharmaceuticals, Inc., a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that it has signed an agreement providing Cadence with an exclusive option to acquire Incline Therapeutics, Inc., a privately held specialty pharmaceutical company.
The performance of commercially available serological tests in real patient samples and the correlates of immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) provided by IgG antibodies are still a matter of debate. A new bioRxiv preprint paper cross-examines the performance of several assays and proclaims the plaque reduction neutralization test (PRNT) as a method of choice.
› Verified 8 days ago
Rodney T. Steff, DO Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 421 Us 31w Byp, Bowling Green, KY 42101 Phone: 270-782-0151 | |
Dr. Daniel R Long, D.O. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 250 Park St, Bowling Green, KY 42101 Phone: 270-745-1000 | |
Dr. Rance Wentworth, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 201 Park St, Bowling Green, KY 42101 Phone: 270-781-5111 Fax: 270-780-0462 | |
Pinky Dalal Gaba, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 427 Us 31w Byp, Bowling Green, KY 42101 Phone: 270-796-8800 Fax: 270-796-9328 | |
Ms. Uma Akkineni, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 250 Park St, Bowling Green, KY 42101 Phone: 270-796-6540 Fax: 270-796-6576 | |
Mohammed Kazimuddin, MD FACC FSCAI Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 825 Second Ave, Ste B1, Bowling Green, KY 42101 Phone: 270-782-0151 Fax: 270-782-7528 | |
Ann Scarlet Monardo, DO Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 484 Golden Autumn Way Ste 201, Bowling Green, KY 42103 Phone: 270-393-2759 |